139 related articles for article (PubMed ID: 31883216)
1. Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction.
Zeng Q; Song Z; Zhao Y; Wu J; Wang L; Ye H; Wang Y; Wu T; Yuan S; Yuan H
Hepatol Res; 2020 May; 50(5):578-587. PubMed ID: 31883216
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy.
Jia S; Zhao Y; Liu J; Guo X; Chen M; Zhou S; Zhou J
Front Pediatr; 2021; 9():784221. PubMed ID: 35087774
[No Abstract] [Full Text] [Related]
5. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
[TBL] [Abstract][Full Text] [Related]
7. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis.
Kuroda H; Fujiwara Y; Abe T; Nagasawa T; Oguri T; Noguchi S; Kamiyama N; Takikawa Y
PLoS One; 2021; 16(4):e0249493. PubMed ID: 33826669
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
9. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
10. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
12. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
13. Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan.
Audière S; Labourdette A; Miette V; Fournier C; Ternifi R; Boussida S; Pouletaut P; Charleux F; Bensamoun SF; Harrison SA; Sandrin L
Ultrasound Med Biol; 2021 Nov; 47(11):3181-3195. PubMed ID: 34373137
[TBL] [Abstract][Full Text] [Related]
14. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Jung KS; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
J Hepatol; 2017 May; 66(5):1022-1030. PubMed ID: 28039099
[TBL] [Abstract][Full Text] [Related]
15. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease.
Shalimar ; Kumar R; Rout G; Kumar R; Yadav R; Das P; Aggarwal S; Gunjan D; Saraya A; Nayak B
Indian J Gastroenterol; 2020 Feb; 39(1):32-41. PubMed ID: 32185692
[TBL] [Abstract][Full Text] [Related]
16. Performance of the Attenuation Imaging Technology in the Detection of Liver Steatosis.
Ferraioli G; Maiocchi L; Savietto G; Tinelli C; Nichetti M; Rondanelli M; Calliada F; Preda L; Filice C
J Ultrasound Med; 2021 Jul; 40(7):1325-1332. PubMed ID: 32960457
[TBL] [Abstract][Full Text] [Related]
17. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
19. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.
Sasso M; Audière S; Kemgang A; Gaouar F; Corpechot C; Chazouillères O; Fournier C; Golsztejn O; Prince S; Menu Y; Sandrin L; Miette V
Ultrasound Med Biol; 2016 Jan; 42(1):92-103. PubMed ID: 26386476
[TBL] [Abstract][Full Text] [Related]
20. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
